Cadrenal Therapeutics target adjusted to $32 from $3 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Cadrenal Therapeutics (CVKD) to $32 from $3 and keeps a Buy rating on the shares following the 1-for-15 reverse stock split.